Source comparison
Tesamorelin vs Growth Hormone: Safety Profile Comparison
Injection Site Reactions 35% (mild-moderate, typically resolving by 12 months) 10–15% (similar localized reactions) Tesamorelin's higher rate likely reflects daily dosing frequency and reconstitution vehicle pH Glucose Dysregulation Risk 5.8% develop impaired
This comparison does not assign a generated winner or score.
- Injection Site Reactions
- 35% (mild-moderate, typically resolving by 12 months)
- 10–15% (similar localized reactions)
- Tesamorelin's higher rate likely reflects daily dosing frequency and reconstitution vehicle pH
- Glucose Dysregulation Risk
- 5.8% develop impaired fasting glucose; 3.2% progress to diabetes over 2 years
- 15–25% develop impaired glucose tolerance; 8–12% progress to diabetes
- GHRH preserves pulsatile secretion and feedback inhibition, reducing sustained hyperglycemia risk
- IGF-1 Supraphysiological Elevation
- <6% exceed 350 ng/mL
- 40–60% exceed 400 ng/mL with standard dosing
- Feedback regulation intact with tesamorelin; exogenous GH bypasses hypothalamic control
- Lipid Panel Changes
- LDL ↓8–12%; HDL ↓4–6%; TG variable
- LDL ↓10–15%; HDL ↑5–10%; TG ↓15–20%
- Exogenous GH shows more favorable lipid profile. Mechanism for tesamorelin's HDL reduction unclear
- Discontinuation Due to AEs
- 6.2% over 26 weeks
- 12–18% over 26 weeks
- Lower dropout rate with tesamorelin reflects milder systemic effects of pulsatile vs continuous GH exposure
- Serious Adverse Events (hospitalization, death)
- 1.8% (no difference vs placebo)
- 3–5% (marginally higher than placebo in long-term studies)
- Tesamorelin's MACE rate indistinguishable from placebo; exogenous GH shows slight elevation in older cohorts